Australia's most trusted
source of pharma news
Thursday, 12 March 2026
Posted 18 January 2024 PM
An Aussie invention has led to the creation of a new US-based neuroscience company focused on advancing first and best in class drugs for central nervous system related conditions.
In a year end update to investors, Boston-based biotherapeutics company, PureTech Health announced the launch of Seaport Therapeutics, a new clinical-stage company based around a lymphatic-targeting drug delivery platform licensed from Monash University researchers in 2017.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.